BCHE and Alzheimer disease: Randomized double-blind, placebo-controlled trials of three second-generation cholinesterase inhibitors (ChEIs) – donepezil, rivastigmine, and galantamine – that enhance synaptic concentrations of acetylcholine have demonstrated modest beneficial treatment effects in mild to moderate AD over 6 to 12 month periods[9-13].